Income Statement
JANUX THERAPEUTICS, INC.
JANX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
167.67 | 109.44 | 81.06 | 75.70 | 36.57 |
|
Research & Development
|
125.90 | 68.39 | 54.92 | 53.44 | 26.24 |
|
Selling, General & Administrative
|
41.77 | 41.05 | 26.14 | 22.26 | 10.33 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-167.67 | -109.44 | -81.06 | -75.70 | -36.57 |
|
Non-Operating Income
|
44.04 | 29.85 | 14.69 | 4.03 | 0.26 |
|
Interest Income
|
- | - | - | - | - |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | - | - |
|
Income Before Tax
|
- | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-113.63 | -68.99 | -58.29 | -63.06 | -32.67 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-167.67 | -109.44 | -81.06 | -75.70 | -36.57 |
|
Earnings Per Share (Basic)
|
-1.83 | -1.28 | -1.32 | -1.52 | - |
|
Diluted EPS
|
-1.83 | -1.28 | -1.32 | -1.52 | - |
|
Weighted Average Shares
|
61.97 | 53.75 | 44.02 | 41.47 | 0.45 |
|
Diluted Weighted Avg Shares
|
61.97 | 53.75 | 44.02 | 41.47 | - |
|
Comprehensive Income
|
- | - | - | - | - |